A9481
AD 198
≥98% (HPLC), solid
Synonym(s):
N-Benzyladriamycin-14-valerate
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C39H43NO12
CAS Number:
Molecular Weight:
717.76
UNSPSC Code:
12352200
Pricing and availability is not currently available.
Assay
≥98% (HPLC)
form
solid
color
red
solubility
DMSO: >10 mg/mL
H2O: insoluble
storage temp.
2-8°C
SMILES string
CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NCc3ccccc3)[C@H](O)[C@H](C)O2)c4c(O)c5C(=O)c6c(OC)cccc6C(=O)c5c(O)c4C1
Biochem/physiol Actions
AD 198 is a PKC-delta activator.
AD 198 is a PKC-delta activator. Phospholipid scramblase 3 (PLS3) is an enzyme that plays a critical role in mitochondrial morphology, functions, and apoptotic response. During apoptosis, activated protein kinase C-delta (PKC-delta) translocates to mitochondria and phosphorylates PLS3. Used to show that PLS3 is a critical downstream effector of PKC-delta in AD 198-induced apoptosis.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R Ganapathi et al.
British journal of cancer, 60(6), 819-826 (1989-12-01)
N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cellular pharmacokinetics and
L Lothstein et al.
Oncology research, 5(6-7), 229-234 (1993-01-01)
N-Benzyladriamycin-14-valerate (AD 198)-resistant murine J774.2 macrophage-like cells (A300) exhibited a novel mechanism of resistance in which P-glycoprotein was overexpressed without decreased AD 198 accumulation. Cross-resistance to Adriamycin (ADR), N-benzyladriamycin, and Adriamycin-14-valerate was due, at least in part, to reduced accumulation
A Harstrick et al.
Anti-cancer drugs, 6(5), 681-685 (1995-10-01)
The new lipophilic anthracycline N-benzyl-adriamycin-14-valerate (AD198) was evaluated for its activity in comparison to doxorubicin in P-glycoprotein (Pgp)-positive and -negative cell lines. AD198 and doxorubicin showed comparable antitumor activity in the Pgp-negative breast cancer cell line MCF-7 and the Pgp-negative
L Lothstein et al.
Cancer research, 52(12), 3409-3417 (1992-06-15)
N-Benzyladriamycin-14-valerate (AD 198) is a highly lipophilic analogue of Adriamycin with novel cytotoxic mechanisms, greater in vivo antitumor activity, and the ability to circumvent multidrug resistance due to P-glycoprotein-mediated drug efflux or decreased topoisomerase II activity. To identify the mechanism(s)
J Brent Roaten et al.
Molecular cancer therapeutics, 1(7), 483-492 (2002-12-14)
Anthracycline antibiotics like doxorubicin (DOX) are known to exert their antitumor effects primarily via DNA intercalation and topoisomerase II inhibition. By contrast, the noncross-resistant cytoplasmically localizing DOX analogue, N-benzyladriamycin-14-valerate (AD 198), only weakly binds DNA and does not inhibit topoisomerase
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
